Limited utility of rapamycin in severe, refractory Wegener's granulomatosis.
作者信息
Koening Curry L, Hernández-Rodríguez José, Molloy Eamonn S, Clark Tiffany M, Hoffman Gary S
机构信息
Cleveland Clinic, Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, Cleveland, OH, USA.
出版信息
J Rheumatol. 2009 Jan;36(1):116-9. doi: 10.3899/jrheum.080664.
OBJECTIVE
We report our experience using rapamycin in patients with Wegener's granulomatosis (WG) who failed to achieve remission with conventional treatment.
METHODS
Eight patients received rapamycin for severe, refractory WG. Clinical outcomes were reviewed retrospectively.
RESULTS
Four patients treated with rapamycin sustained remissions of at least 6 months' duration while receiving prednisone<or=10 mg/day; 2 relapsed during followup. Five patients discontinued rapamycin due to continued disease activity, cancer, or adverse events.
CONCLUSION
Toxicities due to rapamycin were numerous; consistent proof of efficacy in this pilot experience with WG was not seen.
Zotero 插件